NCT01349075View on ClinicalTrials.gov

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

474

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 15, 2021

Study Completion Date

March 15, 2021

Conditions
Hepatocellular Carcinoma
Interventions
RADIATION

TheraSphere

The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT01349075 - TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter